WESTFIELD, N.J., May  19, 2026  (GLOBE NEWSWIRE) -- Amanat Acquisition Corp (the &#34;Company&#34;), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing

AMAN

Amanat Acquisition Corp Announces Pricing of $75 Million Initial Public Offering

Amanat Acquisition Corp Launches IPO to Pursue Healthcare Deals

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>WESTFIELD, N.J., May  19, 2026  (GLOBE NEWSWIRE) -- Amanat Acquisition Corp (the &amp;#34;Company&amp;#34;), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Amanat Acquisition Corp has successfully priced its IPO at $10.00, offering 7,500,000 shares which will trade on Nasdaq. The focus on healthcare can lead to strategic mergers, enhancing value as they seek business combinations.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Amanat Acquisition Corp’s IPO priced at $10.00 per share.</li><li>7,500,000 Class A shares will begin trading today on Nasdaq.</li><li>Company targets mergers in healthcare and related industries.</li><li>Leerink Partners is managing the IPO and has a 45-day over-allotment option.</li><li>The IPO proceeds may impact future business combination opportunities.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Leerink Partners (N/A)</strong>: Acting as the sole bookrunning manager for AMAN&#039;s IPO.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under Corporate Developments as AMAN is launching its IPO, which is a significant step in acquiring potential business combinations in a focused industry.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Strong demand for healthcare SPACs could drive AMAN&#039;s share price up.</li><li>Positive market reception may lead to a surge in trading volume today.</li><li>The approval of new healthcare mergers could substantially increase AMAN&#039;s valuation.</li><li>Success in identifying a business combination could lead to significant price appreciation.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>IPO consists of 7,500,000 Class A ordinary shares at $10.00 each.</li><li>Expected to close on May 20, 2026.</li><li>Share symbol on Nasdaq will be &#039;AMAN&#039;.</li><li>Underwriter has a 45-day option for an additional 1,125,000 shares.</li><li>Company was formed to target healthcare-related business combinations.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying AMAN as it enters the market with substantial growth potential in healthcare.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">WESTFIELD, N.J., May  19, 2026  (GLOBE NEWSWIRE) -- Amanat Acquisition Corp (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 7,500,000 Class A ordinary shares at an offering price of $10.00 per share. The Class A ordinary shares are expected to trade on the Nasdaq Capital Market under the ticker symbol "AMAN" beginning today. The offering is expected to close on May 20, 2026, subject to customary closing conditions.</p>  <p align="justify">The Company is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus on opportunities in healthcare or healthcare-related industries.</p>  <p align="justify">Leerink Partners is acting as sole bookrunning manager. The Company has granted the underwriter a 45-day option to purchase up to 1,125,000 additional Class A ordinary shares at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.</p>  <p align="justify">A registration statement relating to the securities sold in the initial public offering was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on May 18, 2026 (the "Effective Date"). The public offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from Leerink Partners LLC, Attn: Syndicate Department, 1301 Avenue of the Americas, 5th Floor, New York, New York 10019, by email at <a href="https://www.globenewswire.com/Tracker?data=_b_yqWLh5nrmxDZEulsOihAp8DcCutggs73Z4zO7JHDYkHXpBIA8Ml8TPoc7bD6napYu7OdcyHmqBMyM4QvpSUoJB36SSfgiTH6b5Ybwm-s=" rel="nofollow" target="_blank">syndicate@leerink.com</a>.</p>  <p align="justify"> This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>  <p align="justify"><strong>About Amanat Acquisition Corp </strong></p>  <p align="justify">Amanat Acquisition Corp is a recently incorporated blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. While the Company may pursue an initial business combination in any business or industry, the Company intends to focus on healthcare or healthcare-related industries, which can benefit from the expertise and capabilities of the management team in order to create long-term shareholder value. The Company is sponsored by Amanat Sponsor Holdings LLC and is led by Dr. Sandeep C. Kulkarni, its Chairman of the Board, Dr. Pavan Cheruvu, its Director and Chief Executive Officer, and Mr. Nicholas Fernandez, its Chief Financial Officer. The Company's Board of Directors also includes Ms. Rakhi Kumar, Mr. Brad Middlekauff, and Mr. Patrick Crutcher.</p>  <p align="justify"><strong>Forward-Looking Statements</strong></p>  <p align="justify">This press release contains statements that constitute "forward-looking statements," including with respect to the Company's initial public offering ("IPO") including the gross proceeds of the IPO, the anticipated use of the net proceeds from the IPO and the search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or that the net proceeds of the offering will be used as indicated or that the Company will ultimately complete a business combination transaction in the sectors it is targeting or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Amanat Acquisition Corp, including those set forth in the Risk Factors section of Amanat Acquisition Corp's registration statement and preliminary prospectus for the IPO filed with the SEC. Copies are available on the SEC's website, <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>. Amanat Acquisition Corp undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.</p>  <p><strong>Contacts:</strong></p>  <p>Nicholas Fernandez<br></br>Chief Financial Officer<br></br>153 Central Avenue<br></br>C/O 56<br></br>Westfield, NJ 07091<br></br>201-688-0364<br></br><a href="https://www.globenewswire.com/Tracker?data=sto4wqRA_7HWqlEQGx4kvmGn8F7kDPGZJbfqJH4j917v5Zmr40aFqi3afibMpXIWbJlbjA34XsNiM-8l5CjaQ6ZrYjKdwIBUWIdsStqDa85wPCP1W2Jvz97ZUaRWpH2V" rel="nofollow" target="_blank">amanatacquisition.com </a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMzA4OCM3NjExMzAwIzIzMTIwMDg="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZmMzNDA0N2MtZjQ2NS00M2ViLWJhYmYtYjQxOTAyODAyNDc3LTEzMjM1NTgtMjAyNi0wNS0xOS1lbg==/tiny/Amanat-Acquisition-Corp.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/2e57df2a-53e6-419c-930e-e37efaa186fc"><img src="https://ml.globenewswire.com/media/2e57df2a-53e6-419c-930e-e37efaa186fc/small/picture1-jpg.jpg" border="0" width="144" height="37" alt="Primary Logo"></img></a></p>

Amanat Acquisition Corp has successfully priced its IPO at $10.00, offering 7,500,000 shares which will trade on Nasdaq. The focus on healthcare can lead to strategic mergers, enhancing value as they seek business combinations.

Amanat Acquisition Corp Announces Pricing of $75 Million Initial Public Offering

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News